Results 31 to 40 of about 413,985 (241)

Impact of Total Dose Intensity and Relative Dose Intensity (RDI) of R-CHOP on Survival in Patients with DLBCL

Blood, 2018
Abstract Background: The standard chemotherapy for diffuse large B-cell lymphoma (DLBCL) is CHOP combined with rituximab (R-CHOP). The guidelines (e.g. NCCN or ESMO) recommend six to eight courses of R-CHOP and the optimal number of courses is still unclear.
Ayumi Komuro, Sachiko Seo, Nobuo Mochizuki, Yosuke Minami, Toshikatu Kawasaki   +4 more
openaire   +1 more source

Re-Evaluating Chemotherapy Dosing Strategies for Ovarian Cancer: Impact of Sarcopenia

Current Oncology, 2023
We investigated the impact of sarcopenia on adjuvant chemotherapy dosing in advanced epithelial ovarian cancer (EOC). The chemotherapy dosing and toxicity of 173 eligible patients who underwent cytoreductive surgery and adjuvant chemotherapy at a single ...
Rushi Shah, Clarissa Polen-De, Michaela McGree, Angela Fought, Amanika Kumar   +4 more
doaj   +1 more source

Relationship between outcomes and relative dose intensity of lenvatinib treatment in patients with advanced hepatocellular carcinoma

Liver Research, 2020
Background and aims: Lenvatinib (LEN) is a newly developed tyrosine kinase inhibitor, and is approved as a first-line treatment for advanced hepatocellular carcinoma (HCC) in Japan.
Takamasa Ohki, Koki Sato, Mayuko Kondo, Eriko Goto, Takahisa Sato, Yuji Kondo, Masatoshi Akamatsu, Shinpei Sato, Hideo Yoshida, Yukihiro Koike, Shuntaro Obi   +10 more
doaj   +1 more source

Study on the Effect of 4D-CT Special Reconstruction Images for Evaluation of the Cardiac Structure Dose in Radiotherapy for Breast Cancer

Frontiers in Oncology, 2020
Objective: To study the dosimetric effect on special reconstruction images obtained from an electrocardiograph-gated four-dimensional computed tomography (ECG 4D-CT) series and compare it with the accumulation dose assessment of ECG 4D-CT.Methods ...
Ming Su, Guanzhong Gong, Xiaoping Qiu, Ying Tong, Qian Li, Yong Yin   +5 more
doaj   +1 more source

Maintenance therapy for pediatric patients with high-risk Rhabdomyosarcoma: A report of dose reductions and dose omissions on outcome

EJC Paediatric Oncology
Introduction: In the multicenter, open-label, randomized, controlled, phase 3 trial RMS2005, maintenance chemotherapy (MC), defined as vinorelbine (VNL) and low-dose cyclophosphamide (CPM), has been tested in high-risk patients affected by ...
Daniela Di Carlo, Lisa Lyngsie Hjalgrim, Beatrice Coppadoro, Michela Casanova, Andrea Ferrari, Véronique Minard-Colin, Hans Merks, Gianni Bisogno   +7 more
doaj   +1 more source

Clinical and Biological Features of Response in Resistant Neuroblastoma to 131I‐Metaiodobenzylguanidine Radiotherapy in the Anti‐GD2 Immunotherapy Era

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background 131I‐metaiodobenzylguanidine (131I‐MIBG) radiotherapy is a key treatment for relapsed and refractory (R/R) neuroblastoma (NB). Patients with R/R disease treated in the modern era are increasingly exposed to anti‐GD2 immunotherapy, which exerts selective pressure and may modify both tumor cell state and microenvironment.
Benjamin J. Lerman, Katherine K. Matthay, Fabienne Hollinger, Catriona Black, Ann A. Lazar, Miguel Pampaloni, Steven G. DuBois, Kieuhoa T. Vo   +7 more
wiley   +1 more source

Claudin‐6 Protein Expression in Atypical Teratoid/Rhabdoid Tumors Is Strongly Enriched in the Molecular Subgroup AT/RT‐TYR

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Claudin‐6 has emerged as a promising immunotherapeutic target, yet protein‐level data in atypical teratoid/rhabdoid tumors (AT/RTs) have been inconsistent. We analyzed 36 well‐characterized AT/RT samples and found membranous claudin‐6 protein expression in 58% of cases, with striking enrichment in the molecular subgroup AT/RT‐TYR (100%) and ...
Victoria E. Fincke, Christian Thomas, Michael C. Frühwald, Pascal D. Johann, Martin Hasselblatt   +4 more
wiley   +1 more source

Potential utility of a longitudinal relative dose intensity of molecularly targeted agents in phase 1 dose‐finding trials [PDF]

Cancer Science, 2017
Phase 1 trials of molecularly targeted agents (MTA) often do not use toxicity data beyond the first cycle of treatment to determine a recommended phase 2 dose (RP2D). We investigated the potential utility of longitudinal relative dose intensity (RDI) that may be a better new way of determining a more accurate RP2D as a lower dose that is presumably ...
Akihiro Hirakawa, Kan Yonemori, Fumie Kinoshita, Yumiko Kobayashi, Hitomi S. Okuma, Asuka Kawachi, Kenji Tamura, Yasuhiro Fujiwara, Larry Rubinstein, Pamela Jo Harris, Naoko Takebe   +10 more
openaire   +2 more sources

Time Toxicity in Wilms Tumor: Quantifying the Burden of Healthcare Interaction in the First Year After Diagnosis

Pediatric Blood &Cancer, EarlyView.
ABSTRACT Background Wilms tumor (WT) treatment imposes a significant time burden on patients and their families. Time toxicity is a patient‐centered metric that quantifies the burden of healthcare interaction. We sought to define time toxicity in the first year after diagnosis of WT and hypothesized that it would increase as tumor stage and treatment ...
Caleb Q. Ashbrook, Veerain Gupta, Nicholas J. Clark, Vijay Rings, Lauren E. Corona, Douglass B. Clayton, Daniel J. Benedetti   +6 more
wiley   +1 more source

Impact of dose intensity on outcome of fludarabine, cyclophosphamide, and rituximab regimen given in the first-line therapy for chronic lymphocytic leukemia

Haematologica, 2013
Fludarabine-cyclophosphamide-rituximab is the most efficient first-line treatment for chronic lymphocytic leukemia patients. Many dose adjustments of the original MD Anderson Cancer Center regimen have been proposed.
Emmanuelle Bouvet, Cécile Borel, Lucie Obéric, Gisèle Compaci, Bruno Cazin, Anne-Sophie Michallet, Guy Laurent, Loic Ysebaert   +7 more
doaj   +1 more source